Abstract
Two decades ago the National Surgical Adjuvant Breast Project (NSABP) began to test the hypothesis that adjuvant chemotherapy would influence favorably the postsurgical survival rates of women with breast cancer. Although the use of phenylalanine mustard (melphalan or (L-PAM) has been supplemented by other agents, the thrust to recommend adjuvant chemotherapy as standard treatment was created by an L-PAM series of five trials using L-PAM or L-PAM plus fluorouracil. Only the first trial, B-05, contained an untreated group. The main treated groups in these five trials are similar to each other in survival probabilities, and the main untreated group in B-05 is not different in survival than the combined results of these five trials. There were a total of nine comparison in each study-and in B-05 the subgroup of treated women 49 years or younger with one to three positive node was found to be different than the untreated group. Four subsequent subgroups of women who were 49 years or younger with one to three positive nodes are not similar in survival despite the fact that they were developed from similar main groups that had similar treatment. The initial treated subgroup in B-05 had a survival outcome that was never again achieved in the subsequent four studies. The untreated subgroup in B-05 was not different than three of the four subsequently treated subgroups. The NSABP now has evidence that denies the conclusion that adjuvant chemotherapy prolongs survival in premenopausal node-positive women. Recommendations that adjuvant chemotherapy become standard treatment for premenopausal node-positive women should be seriously reconsidered and probably withdrawn.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fisher B., Carbone P., Economou S. G., Frelick R., Glass A., Lerner H., Redmond C., Zelen M., Band P., Katrych D. L. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975 Jan 16;292(3):117–122. doi: 10.1056/NEJM197501162920301. [DOI] [PubMed] [Google Scholar]
- Fisher B., Fisher E. R., Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986 Jun;4(6):929–941. doi: 10.1200/JCO.1986.4.6.929. [DOI] [PubMed] [Google Scholar]
- Fisher B., Glass A., Redmond C., Fisher E. R., Barton B., Such E., Carbone P., Economou S., Foster R., Frelick R. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer. 1977 Jun;39(6 Suppl):2883–2903. doi: 10.1002/1097-0142(197706)39:6<2883::aid-cncr2820390676>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
- Fisher B., Redmond C., Elias E. G., Evans J., Foster R., Jochimsen P., Lawrence W., Lerner H., LiCalzi N., Margolese R. Adjuvant chemotherapy for breast cancer: an overview of NSABP findings. Int Adv Surg Oncol. 1982;5:65–90. [PubMed] [Google Scholar]
- Fisher B., Redmond C., Fisher E. R., Wolmark N. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. NCI Monogr. 1986;(1):35–43. [PubMed] [Google Scholar]
- Fisher E. R., Redmond C., Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer. 1983 Jan 15;51(2):181–191. doi: 10.1002/1097-0142(19830115)51:2<181::aid-cncr2820510202>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
- Richards M. A., O'Reilly S. M., Howell A., George W. D., Fentiman I. S., Chaudary M. A., Crowther D., Rubens R. D. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol. 1990 Dec;8(12):2032–2039. doi: 10.1200/JCO.1990.8.12.2032. [DOI] [PubMed] [Google Scholar]